The Lancet. Respiratory medicine
The most recent articles from:
Lancet Respir Med
-
Randomized Controlled Trial Multicenter Study
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We aimed to assess the efficacy and safety of pirfenidone in patients with progressive fibrosing unclassifiable ILD. ⋯ F Hoffmann-La Roche.